Related Experiment Videos
Clinically-oriented therapies in sepsis: a review
1Department of Intensive Care, Erasme Hospital, Free University of Brussels, Belgium.
Abstract:
Our insight of the sepsis response has evolved to encompass not only the pro-inflammatory but also an anti-inflammatory reaction following infection. Clinical trials have been designed to target either bacterial products, endotoxin in particular, or mediators involved in the sepsis response, but until recently the majority of them have given unfavorable results. In this article, we provide a scope of clinical trials that have been done in immunomodulation during sepsis whether or not they provide positive results. We will also discuss some of the reasons why those studies have been disappointing. Current and future trials with a better assessment of inflammatory status of patients and better-defined outcomes such as organ dysfunction are now underway.
Insights
Sepsis treatment trials targeting inflammation have yielded poor results. Future studies will better assess patient inflammatory status and organ dysfunction for improved outcomes in sepsis management.
Area of Science:
- Immunology
- Critical Care Medicine
- Infectious Diseases
Background:
- Sepsis involves complex pro-inflammatory and anti-inflammatory responses.
- Previous clinical trials targeting bacterial products or inflammatory mediators in sepsis have largely failed.
Purpose of the Study:
- To review clinical trials on immunomodulation in sepsis.
- To discuss reasons for disappointing trial outcomes.
- To highlight future directions in sepsis research.
Main Methods:
- Comprehensive review of published clinical trials in sepsis immunomodulation.
- Analysis of trial designs, targets, and outcomes.
- Discussion of factors contributing to trial success or failure.
Main Results:
- The majority of immunomodulatory sepsis trials have reported unfavorable results.
- Targeting endotoxins or specific mediators has not consistently improved sepsis outcomes.
- Challenges include patient heterogeneity and outcome definitions.
Conclusions:
- Past immunomodulatory strategies for sepsis have been largely unsuccessful.
- Improved patient stratification and outcome measures are crucial for future sepsis trials.
- Ongoing trials focus on better inflammatory status assessment and organ dysfunction outcomes.